Advanced SearchSearch Tips
Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : BMB Reports
  • Volume 48, Issue 10,  2015, pp.565-570
  • Publisher : Korean Society for Biochemistry and Molecular Biology
  • DOI : 10.5483/BMBRep.2015.48.10.268
 Title & Authors
Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines
Choi, Song Hee; Park, Byoung Kwon; Lee, Keun-Wook; Chang, Jun; Lee, Younghee; Kwon, Hyung-Joo;
  PDF(new window)
In several reports, the respiratory syncytial virus (RSV) was identified as an oncolytic virus in cancer cells (e.g., lung and prostate cancer). However, the effects of RSV in hepatocellular carcinoma (HCC) cells have not yet been investigated. Here, we observed the inhibitory effects of RSV infection in HCC cell-lines. Cell growth was significantly decreased by RSV infection in BNL-HCC, Hep3B, Huh-7 and SNU-739 cells. After RSV infection, plaque formation and syncytial formation were observed in affected Hep3B and Huh-7 cells. RSV protein-expression was also detected in Hep3B and Huh-7 cells; however, only Huh-7 cells showed apoptosis after RSV infection. Furthermore, inhibition of cell migration by RSV infection was observed in BNL-HCC, Hep3B, Huh-7 and SNU-739 cells. Therefore, further investigation is required to clarify the molecular mechanism of RSV-mediated inhibition of HCC cell growth, and to develop potential RSV oncolytic viro-therapeutics.
Apoptosis;Cell growth;Hepatocellular carcinoma;Oncolytic effect;RSV;
 Cited by
N-Adamantyl-4-methylthiazol-2-amine suppresses amyloid β-induced neuronal oxidative damage in cortical neurons, Free Radical Research, 2016, 50, 6, 678  crossref(new windwow)
Parkin DM, Bray F, Ferlay J and Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 crossref(new window)

Forver A, Llivet JM and Bruix (2012) Hepatocellular carcinoma. Lancet 379, 1245-1255 crossref(new window)

El-Serag HB and Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 crossref(new window)

Hoofnagle JH (2004) Hepatocellular carcinoma: summary and recommendations. Gastroenterology 127, S319-S323 crossref(new window)

Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45, 529-538 crossref(new window)

Douek M and Taylor I (2003) Good practice and quality assurance in surgical oncology. Lancet Oncol 4, 626-630 crossref(new window)

Llovet JM, Burroughs A and Bruix J (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917 crossref(new window)

Avila MA , Berasain C, Sangro B and Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25, 3866-3884 crossref(new window)

Woller N, Gürlevik E, Ureche CI, Schumacher A and Kühnel F (2014) Oncolytic viruses as anticancer vaccines. Front Oncol 4, 188 crossref(new window)

Russell SJ, Peng KW and Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30, 658-670 crossref(new window)

Liu TC, Hwang T, Park BH, Bell J and Kirn DH (2008) The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16, 1637-1642 crossref(new window)

Kim JH, Oh JY, Park BH et al (2006) Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF. Mol Ther 14, 361-370 crossref(new window)

Heo J, Breitbach CJ, Moon A et al (2011) Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 19, 1170-1179 crossref(new window)

Heo J, Reid T, Ruo L et al (2013) Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19, 329-336 crossref(new window)

Chang J (2011) Current progress on development of respiratory syncytial virus vaccine. BMB Rep 44, 232-237 crossref(new window)

Atreya PL and Kulkarni S (1999) Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 261, 227-241 crossref(new window)

Tregoning JS and Schwarze J (2010) Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 23, 74-98 crossref(new window)

Falsey AR and Walsh EE (2000) Respiratory syncytial virus infection in adults.Clin Microbiol Rev 13, 371-384 crossref(new window)

Echchgadda I, Kota S, DeLa Cruz I et al (2009) Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther 16, 923-935 crossref(new window)

Echchgadda I, Chang TH, Sabbah A et al (2011) Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense. BMC Cancer 11, 43 crossref(new window)

Salimi V, Tavakoli-Yaraki M, Mahmoodi M et al (2013) The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431. Iran Red Crescent Med J 15, 62-67 crossref(new window)

Kelly E and Russell SJ (2007) History of Oncolytic Viruses: Genesis to Genetic Engineering. Mol Ther 15, 651-659 crossref(new window)

Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7, 781-787 crossref(new window)

Bell JC (2007) Oncolytic viruses: what's next? Curr Cancer Drug Targets 7, 127-131 crossref(new window)

Stanford MM and McFadden G (2007) Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 7, 1415-1425 crossref(new window)

Mohr I (2005) To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 24, 7697-7709 crossref(new window)

Everts B and van der Poel HG (2005) Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12, 141-161 crossref(new window)

Parato KA, Senger D, Forsyth PA and Bell JC (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5, 965-976 crossref(new window)

Kim HR, Heo YM, Jeong KI et al (2012) FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB Rep 45, 287-292 crossref(new window)

Youn JK, Kim DW, Kim ST et al (2014) PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson’s disease mouse model. BMB Rep 47, 569-574 crossref(new window)

Kim S and Chang J (2012) Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease. Immune Netw 12, 8-17 crossref(new window)

Lee YD, Cui MN, Yoon HH, Kim HY, Oh IH and Lee JH (2014) Down-modulation of Bis reduces the invasive ability of glioma cells induced by TPA, through NF-kB mediated activation of MMP-9. BMB Rep 47, 262-267 crossref(new window)

Kim DS, Sohn EJ, Kim DW et al (2012) PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression. BMB Rep 45, 532-537 crossref(new window)